These preclinical findings translate to clinical observations, demonstrating that while personalized neoepitope-specific vaccines induce CD4+ rather than CD8+ T cell responses in cancer patients [23, 24], mutation-specific CD4+ T-helper cells are capable of eradicating large tumors in cancer patients [25]. This evidence concerns the gene CD8A and cancer.